Abstract
Redox status disturbances are known during carcinogenesis and may have influence on patients’ survival. However, the prediction of mortality in lung cancer patients based on serum total SOD activity, and concentrations of its isoforms, has not been studied to date. This prospective cohort study has following aims: (1) to evaluate the disturbances in serum SOD activity and SOD1/2 concentrations; (2) to assess the implications of these alterations with regard to biochemical variables and clinical data, and (3) to investigate the association between serum SOD activity, SOD1/2 concentrations, and all-cause mortality in lung cancer patients. Serum total SOD activity and SOD1, SOD2, albumin, CRP, and ceruloplasmin concentrations were determined in lung cancer patients (n = 190) and control subjects (n = 52). Additionally, patients were characterized in terms of biochemical, clinical, and sociodemographic data. Multiple Cox regression models were used to estimate the association between all-cause death and SOD-related parameters. All-cause mortality in lung cancer was positively associated with serum SOD1 and SOD2 concentrations. Clinical stage III and IV disease was the strongest predictor. The utility of the evaluated parameters in predicting overall survival was demonstrated only for SOD1. Serum SOD1 and SOD2 concentrations were shown to positively affect all-cause mortality in lung cancer patients, but SOD1 seems to be a better predictor than SOD2.
Highlights
Introduction iationsRecent global cancer statistics indicate that lung cancer is still the most commonly diagnosed cancer among men in countries of low socioeconomic status
The median serum SOD1 and SOD2 concentrations were significantly higher in lung cancer patients compared to control subjects (218.9 vs. 141.0 pg/mL, and 1.30 vs. 0.78 ng/mL, respectively)
This study was designed to evaluate the following hypotheses: (1) serum superoxide dismutase (SOD) activity and SOD1/2 concentrations are changed in lung cancer patients; (2) these alterations are related to both biochemical variables and clinical data, and (3) serum SOD
Summary
Recent global cancer statistics indicate that lung cancer is still the most commonly diagnosed cancer among men in countries of low socioeconomic status. It remains the most common cause of oncological deaths, regardless of sex and economic status [1,2]. The average five-year survival rate for lung cancer patients in the United States is reported to be approximately 17% [3], and that in Europe is approximately. As lung cancer remains the leading cause of cancer-related death worldwide [2], the identification and availability of prognostic markers is important in the management of patients in order to increase survival outcomes. The utilization of early prognostic biomarkers can markedly increase the efficiency of therapy, detection of Licensee MDPI, Basel, Switzerland
Sign-in/Register to view highlights & summary Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callDisclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
